Literature DB >> 25239391

Bladder dysfunction in presymptomatic gene carriers and patients with Huntington's disease.

Matej Kolenc1, Metka Moharić, Jan Kobal, Simon Podnar.   

Abstract

The objective of this study was to report bladder dysfunction and cystometric findings in a systematically studied cohort of Huntington's disease (HD) patients. In HD patients and asymptomatic HD gene carriers a urinary function questionnaire, neurologic assessment using the Unified Huntington's Disease Rating Scale, and postvoid residual volume measurement were applied. All patients were also invited to cystometric studies. Urinary function data were compared to control men and women. The most common symptoms in 54 HD patients (24 men) were those of bladder overactivity (men/women 54%/40%), followed by urinary incontinence (29%/43%) and symptoms of disturbed bladder emptying (25%/40%). Using urinary function questionnaires severe bladder dysfunction was found in 4%/0%, moderate in 21%/23%, and mild in 25%/30% of HD men/women. Urinary symptoms interfered with daily life in 21%/37% and sexual life in 21%/33% of sexually active HD men/women. In 5 HD men and 1 woman, increased postvoid residual volume (>100 ml) was found. Compared to 49/55 control men/women urinary incontinence, and urgency were more common in HD men, but not in HD women (urinary incontinence reported 10%/38% of control men/women). Cystometry, performed in 12 HD patients and 1 of 10 asymptomatic HD gene carriers, demonstrated detrusor-sphincter dyssynergia in 5 (42%), detrusor overactivity in 2 (17%), and reduced detrusor capacity in 2 (17%) HD patients. Our study demonstrated significant urinary symptoms in HD patients, which reduced their quality of life. Physicians helping HD patients should also consider this largely neglected aspect of the disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25239391     DOI: 10.1007/s00415-014-7494-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  40 in total

1.  Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies.

Authors:  Werner Schäfer; Paul Abrams; Limin Liao; Anders Mattiasson; Francesco Pesce; Anders Spangberg; Arthur M Sterling; Norman R Zinner; Philip van Kerrebroeck
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms.

Authors:  I Araki; M Kitahara; T Oida; S Kuno
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

3.  Huntington disease: clinical care and evaluation.

Authors:  I Shoulson; S Fahn
Journal:  Neurology       Date:  1979-01       Impact factor: 9.910

4.  Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

Authors:  Sarah J Tabrizi; Ralf Reilmann; Raymund A C Roos; Alexandra Durr; Blair Leavitt; Gail Owen; Rebecca Jones; Hans Johnson; David Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2011-12-02       Impact factor: 44.182

5.  No electrophysiological evidence for Onuf's nucleus degeneration causing bladder and bowel symptoms in Huntington's disease patients.

Authors:  Matej Kolenc; Jan Kobal; Simon Podnar
Journal:  Neurourol Urodyn       Date:  2013-06-26       Impact factor: 2.696

6.  Escitalopram-associated acute urinary retention.

Authors:  Dominick Trombetta; Kathleen Garrett; Marissa Harrison
Journal:  Consult Pharm       Date:  2013-10

7.  Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia.

Authors:  Frédéric Bloch; Bertrand Pichon; Anne-Marie Bonnet; Jacques Pichon; Marie Vidailhet; Emmanuel Roze; Michel Perrigot
Journal:  J Neurol       Date:  2010-08-04       Impact factor: 4.849

8.  Standardization of anal sphincter electromyography: quantification of continuous activity during relaxation.

Authors:  Simon Podnar; Mićo Mrkaić; David B Vodusek
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

9.  Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease.

Authors:  N A Aziz; G V Anguelova; J Marinus; J G van Dijk; R A C Roos
Journal:  Eur J Neurol       Date:  2010-02-24       Impact factor: 6.089

10.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Gail Owen; Alexandra Durr; Blair R Leavitt; Raymund A Roos; Beth Borowsky; Bernhard Landwehrmeyer; Chris Frost; Hans Johnson; David Craufurd; Ralf Reilmann; Julie C Stout; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2013-05-09       Impact factor: 44.182

View more
  4 in total

1.  Non-motor symptoms in Huntington's disease: a comparative study with Parkinson's disease.

Authors:  Tatiana Aldaz; Pasquale Nigro; Almudena Sánchez-Gómez; Celia Painous; Lluís Planellas; Pilar Santacruz; Ana Cámara; Yaroslau Compta; Francesc Valldeoriola; Maria J Martí; Esteban Muñoz
Journal:  J Neurol       Date:  2019-03-05       Impact factor: 4.849

Review 2.  A Review of Scales to Evaluate Sleep Disturbances in Movement Disorders.

Authors:  Mónica M Kurtis; Roberta Balestrino; Carmen Rodriguez-Blazquez; Maria João Forjaz; Pablo Martinez-Martin
Journal:  Front Neurol       Date:  2018-05-29       Impact factor: 4.003

3.  Hypertension, Antihypertensive Use and the Delayed-Onset of Huntington's Disease.

Authors:  Jessica J Steventon; Anne E Rosser; Emma Hart; Kevin Murphy
Journal:  Mov Disord       Date:  2020-02-04       Impact factor: 10.338

4.  Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington's disease.

Authors:  Tiberiu Loredan Stan; Rana Soylu-Kucharz; Stephen Burleigh; Olena Prykhodko; Ling Cao; Naomi Franke; Marie Sjögren; Caroline Haikal; Frida Hållenius; Maria Björkqvist
Journal:  Sci Rep       Date:  2020-10-26       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.